SCHEMBL7933846

SCHEMBL7933846

CN(C)S(=O)(=O)c1ccc(N)c(O)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.58
MEN1 O00255 3/20 0.58
KMT2A Q03164 3/20 0.58
PKM P14618 2/20 0.58
POLB P06746 1/20 0.58
SERPINE1 P05121 3/20 0.55
HSD17B10 Q99714 2/20 0.47
CYP3A4 P08684 1/20 0.47
ALOX15 P16050 1/20 0.47
MAPT P10636 3/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
GAA P10253 2/20 0.44
HTT P42858 2/20 0.44
LMNA P02545 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA9 Q16790 1/20 0.44
KDM4E B2RXH2 2/20 0.43
RAB9A P51151 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6937115 0.85 MAPT (0.63) ALDH1A1MEN1KMT2APKMPOLB
SCHEMBL11492952 0.82 SERPINE1 (0.78) ALDH1A1MEN1KMT2APKMPOLB
SCHEMBL914479 0.82 ALDH1A1 (0.64) ALDH1A1MEN1KMT2APKMPOLB
SCHEMBL5623940 0.79 ALDH1A1 (0.60) ALDH1A1MEN1KMT2APKMPOLB
SCHEMBL6932811 0.79 G6PD (0.58) ALDH1A1MEN1KMT2APKMPOLB
SCHEMBL1732418 0.78 GAA (0.69) ALDH1A1MEN1KMT2APKMPOLB
SCHEMBL745596 0.78 ALDH1A1 (0.73) ALDH1A1MEN1KMT2APKMHSD17B10
SCHEMBL30473321 0.78 GAA (0.69) ALDH1A1MEN1KMT2APKMPOLB
SCHEMBL30460505 0.78 ALDH1A1 (0.73) ALDH1A1MEN1KMT2APKMHSD17B10
SCHEMBL29400283 0.78 GAA (0.69) ALDH1A1MEN1KMT2APKMPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119161846-A Antistatic UV (ultraviolet) mucosa-reducing agent and preparation method thereof 江苏斯瑞达材料技术股份有限公司 2024-12-20 CN claimed
US-6280923-B1 LIGHT-INSENSITIVE SILVER SALT OF AN ORGANIC CARBOXYLIC ACID; PHOTOSENSITIVE SILVER HALIDE; BINDER; ORGANIC REDUCING AGENT FOR SAID SUBSTANTIALLY LIGHT-INSENSITIVE SILVER SALT AGFA-GEVAERT (BE) 2001-08-28 US claimed
US-12570620-B2 Covalent inhibitors of creatine kinase (CK) and uses thereof for treating and preventing cancer DANA-FARBER CANCER INSTITUTE, INC. (US) 2026-03-10 US disclosed
CN-119161846-A Antistatic UV (ultraviolet) mucosa-reducing agent and preparation method thereof 江苏斯瑞达材料技术股份有限公司 2024-12-20 CN disclosed
CN-119161846-A Antistatic UV (ultraviolet) mucosa-reducing agent and preparation method thereof 江苏斯瑞达材料技术股份有限公司 2024-12-20 CN disclosed
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. 2023-12-14 US disclosed
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. 2023-12-14 US disclosed
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. 2023-12-14 US disclosed
EP-4232161-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER Dana-Farber Cancer Institute, Inc. (US) 2023-08-30 EP disclosed
CN-116323571-A Covalent inhibitors of Creatine Kinase (CK) and their use for the treatment and prevention of cancer 丹娜法伯癌症研究院 2023-06-23 CN disclosed
WO-2022087433-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER DANA-FARBER CANCER INSTITUTE, INC. (US) 2022-04-28 WO disclosed
EP-0384893-A1 Process for the preparation of asymmetrical 1,2-metal complex dyestuffs CIBA-GEIGY AG (CH) 1990-08-29 EP disclosed
US-4560744-A FOR NYLON AND NATURAL POLYAMIDES BASF AKTIENGESELLSCHAFT (DE) 1985-12-24 US disclosed
US-4524123-A POLYETHERSILOXANE COPOLYMERS, HIGH MOLECULAR WEIGHT POLYETHYLEN, AND EMULSIFIER AGFA-GEVAERT AKTIENGESELLSCHAFT (DE) 1985-06-18 US disclosed
EP-0054230-B1 MONOAZO DYESTUFFS AND USE AS IMAGE-FORMING DYESTUFFS IN COLOUR-PHOTOGRAPHIC REGISTRATION MATERIALS Agfa-Gevaert AG (DE) 1985-03-20 EP disclosed
EP-0037904-B1 METAL-COMPLEX DYESTUFFS BASF Aktiengesellschaft (DE) 1983-12-28 EP disclosed
US-4396710-A Photographic recording material with metal complexable, heterocyclic azo dye AFGA-GEVAERT AKTIENGESELLSCHAFT (DE) 1983-08-02 US disclosed
EP-0054230-A2 Monoazo dyestuffs and use as image-forming dyestuffs in colour-photographic registration materials Agfa-Gevaert AG (DE) 1982-06-23 EP disclosed
EP-0037904-A1 Metal-complex dyestuffs BASF Aktiengesellschaft (DE) 1981-10-21 EP disclosed
US-4264494-A Chromium complex dyestuffs for natural polyamides and synthetic nylons BASF AKTIENGESELLSCHAFT (DE) 1981-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12570620-B2 Covalent inhibitors of creatine kinase (CK) and uses thereof for treating and preventing cancer CSNK1A1L, CKMT1A; CKMT1B, KHK ALDH1A1 1714/4885MEN1 4864/4885KMT2A 476/4885
US-20230399304-A1 COVALENT INHIBITORS OF CREATINE KINASE (CK) AND USES THEREOF FOR TREATING AND PREVENTING CANCER CKMT1A; CKMT1B, PHKG1, PCK1 ALDH1A1 924/4885MEN1 4455/4885KMT2A 464/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.